Kirin

Results: 783



#Item
121

Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S. (NEW YORK and TOKYO, July 29, Kyowa Ha

Add to Reading List

Source URL: www.kyowa-kirin.com

Language: English - Date: 2015-07-29 19:00:03
    122

    January 31, 2014 Kyowa Hakko Kirin Co., Ltd. Appendix to the Fiscal 2013 Consolidated Financial Statements

    Add to Reading List

    Source URL: www.kyowa-kirin.com

    Language: English - Date: 2014-01-30 23:55:16
      123

      FOR IMMEDIATE RELEASE March 31, 2015 Listed Company Name: Kyowa Hakko Kirin Co., Ltd. Representative: Nobuo Hanai, President and CEO (Code no.: 4151, First Section of TSE) Inquiries: Shigeru Morotomi, Executive Officer

      Add to Reading List

      Source URL: www.kyowa-kirin.com

      Language: English - Date: 2015-03-30 20:10:04
        124

        FOR IMMEDIATE RELEASE March 28, 2014 Listed Company Name: Kyowa Hakko Kirin Co., Ltd. Representative: Nobuo Hanai, President and CEO (Code no.: 4151, First Section of TSE) Inquiries: Shigeru Morotomi, Executive Officer

        Add to Reading List

        Source URL: www.kyowa-kirin.com

        Language: English - Date: 2014-03-28 02:40:04
          125

          Press release Cantargia licenses BioWa POTELLIGENT® Technology plat form for production of lead product candidate Lund, Sweden and La Jolla, CA, USA, June 26, 2015. Cantargia AB (CANTA:SS) and BioWa Inc. today

          Add to Reading List

          Source URL: www.kyowa-kirin.com

          Language: English - Date: 2015-06-29 01:00:02
            126

            ONO PHARMACEUTICAL CO., LTD. Bristol-Myers Squibb Company Kyowa Hakko Kirin Co., Ltd. ONO PHARMACEUTICAL, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolu

            Add to Reading List

            Source URL: www.kyowa-kirin.com

            Language: English - Date: 2014-12-10 01:00:04
              127

              FOR IMMEDIATE RELEASE February 26, 2014 Listed Company Name: Kyowa Hakko Kirin Co., Ltd. Representative: Nobuo Hanai, President and CEO (Code no.: 4151, First Section of Tokyo) Inquiries: Shigeru Morotomi, Executive Offi

              Add to Reading List

              Source URL: www.kyowa-kirin.com

              Language: English - Date: 2014-02-26 00:10:02
                128

                Kyowa Hakko Kirin Enters Option Agreement with AstraZeneca for Commercialisation of Benralizumab (KHK4563) in Japan Tokyo, Japan, July 16th, 2015—Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai

                Add to Reading List

                Source URL: www.kyowa-kirin.com

                Language: English - Date: 2015-07-21 21:00:16
                  129

                  Fujifilm Kyowa Kirin Biologics establishes joint venture with AstraZeneca to develop and commercialise anti-VEGF biosimilar July 24, 2015 FUJIFILM Corporation Kyowa Hakko Kirin Co., Ltd. FUJIFILM KYOWA KIRIN BIOLOGICS Co

                  Add to Reading List

                  Source URL: www.kyowa-kirin.com

                  Language: English - Date: 2015-07-24 02:00:04
                    130

                    FOR IMMEDIATE RELEASE March 10, 2014 Listed Company Name: Kyowa Hakko Kirin Co., Ltd. Representative: Nobuo Hanai, President and CEO (Code no.: 4151, First Section of Tokyo) Inquiries: Shigeru Morotomi, Executive Officer

                    Add to Reading List

                    Source URL: www.kyowa-kirin.com

                    Language: English - Date: 2014-03-10 00:10:04
                      UPDATE